HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Leydig cell hyperplasia of testis — Clinical Guidelines

Overview

Leydig cell hyperplasia refers to an increase in the number of Leydig cells within the testis, often observed in contexts of impaired spermatogenesis and certain testicular disorders 12. This condition is clinically significant as it can correlate with decreased testosterone production relative to Leydig cell volume, impacting male fertility 12. Typically identified through testicular biopsies, Leydig cell hyperplasia affects men presenting with infertility or testicular pathologies, highlighting the need for careful histological assessment 12. Understanding this condition aids in differentiating between benign hyperplasia and pathological states, guiding appropriate clinical management and treatment strategies. 12 Leydig cell micronodules are a common finding in testicular biopsies from men with impaired spermatogenesis and are associated with decreased testosterone/LH ratio.

Pathophysiology Leydig cell hyperplasia of the testis refers to an increase in the number or size of Leydig cells, which are responsible for testosterone production 12. This condition often arises in the context of impaired spermatogenesis and is frequently observed in men with nonobstructive azoospermia or testicular disorders 14. The underlying pathophysiology involves several interconnected mechanisms: 1. Hormonal Imbalance and Feedback Mechanisms: In conditions leading to Leydig cell hyperplasia, there is typically a disruption in the hypothalamic-pituitary-gonadal (HPG) axis. Reduced luteinizing hormone (LH) levels due to hypothalamic or pituitary dysfunction can initially trigger compensatory mechanisms, leading to increased expression and proliferation of Leydig cells to maintain testosterone production 12. However, this compensatory response often fails to restore normal spermatogenesis, resulting in persistent hormonal imbalances 14. The elevated LH levels in response to hypogonadal states can stimulate Leydig cell hypertrophy and hyperplasia, though the distinction between hypertrophy (increase in cell size) and hyperplasia (increase in cell number) can be nuanced 12. 2. Oxidative Stress and Cellular Protection: Oxidative stress plays a significant role in the pathogenesis of testicular disorders, including conditions associated with Leydig cell hyperplasia 10. Increased expression of heme oxygenase-1 (HO-1), an antioxidant enzyme, has been noted to protect Leydig cells from oxidative damage, potentially contributing to the observed hyperplasia 10. However, chronic oxidative stress can paradoxically lead to cellular damage and dysfunction, affecting testosterone synthesis and secretion 10. 3. Tissue Remodeling and Cellular Adaptation: The hyperplasia observed in Leydig cells may reflect an adaptive response to chronic testicular stressors such as varicocele, which increases intra-testicular pressure and oxidative stress 7. This remodeling can alter the interstitial environment, impacting Leydig cell function and testosterone production 7. Additionally, the presence of micronodules in Leydig cells, indicative of altered cellular architecture, is associated with decreased testosterone/LH ratios, suggesting impaired hormonal regulation 12. These pathophysiological processes collectively contribute to the complex clinical presentation of Leydig cell hyperplasia, often manifesting as impaired spermatogenesis alongside hormonal imbalances, underscoring the need for comprehensive diagnostic evaluation and tailored therapeutic approaches 12 14.

Epidemiology Leydig cell hyperplasia within the context of testicular pathology is less commonly discussed in epidemiological terms compared to other testicular conditions such as varicocele or certain forms of testicular cancer 12. However, based on available literature, Leydig cell hyperplasia often emerges in clinical contexts related to impaired spermatogenesis and testicular disorders rather than as a standalone prevalent condition 12. Specifically, studies focusing on Leydig cell changes often appear within the scope of testicular biopsies conducted on individuals experiencing nonobstructive azoospermia or infertility 14. These conditions predominantly affect adult males, with no specific age range highlighted distinctly beyond infertility concerns typically diagnosed in reproductive-aged adults 14. Geographically, there is limited specific data delineating regional variations in the incidence of Leydig cell hyperplasia. However, similar testicular pathologies including Leydig cell abnormalities tend to exhibit patterns influenced by broader lifestyle and environmental factors, such as diet and occupational exposures 12. For instance, metabolic disorders linked to high-fructose diets, which can impact Leydig cell function and overall testicular health 3, are more prevalent in regions with higher consumption of processed foods 3. Sex distribution is predominantly male, aligning with the condition's relevance to spermatogenesis and male fertility 12. Prevalence data specifically for Leydig cell hyperplasia alone are sparse, suggesting it may be overshadowed by broader diagnostic categories or not frequently isolated as a distinct epidemiological entity in clinical studies 12. Thus, while specific epidemiological trends are challenging to delineate due to limited focused studies, the condition likely correlates with broader patterns of male reproductive health issues observed globally 12. References:

3 High-fructose diet during puberty alters the sperm parameters, testosterone concentration, and histopathology of testes and epididymis in adult Wistar rats. 12 Leydig cell micronodules are a common finding in testicular biopsies from men with impaired spermatogenesis and are associated with decreased testosterone/LH ratio.

Clinical Presentation Symptoms:

Leydig cell hyperplasia of the testis is often asymptomatic but can be associated with several clinical manifestations, particularly in the context of infertility or testicular disorders 12. Patients may present with: - Decreased fertility: A common finding is impaired spermatogenesis, often linked with Leydig cell micronodules and an altered testosterone/LH ratio 12.

Testicular pain or discomfort: While less common, some individuals may report mild discomfort or pain, though this is not universally reported 17.

Varicocele association: Hyperplasia may coexist with varicocele, where patients might experience testicular enlargement and discomfort 27. Red-Flag Features:

Sudden testicular enlargement or asymmetry: These could indicate underlying pathologies such as testicular tumors, which should prompt further investigation 12.

Decreased testosterone levels with elevated LH: This combination suggests primary hypogonadism rather than Leydig cell hyperplasia alone and warrants further diagnostic evaluation 12.

Presence of Leydig cell tumors: Although rare, Leydig cell hyperplasia can sometimes be associated with Leydig cell tumors, which may present with hormonal imbalances (e.g., increased testosterone levels) and should be ruled out through imaging and hormonal assays 12. Note: The differentiation between hyperplasia and hypertrophy is crucial, as Leydig cell hypertrophy without hyperplasia, as seen in nonobstructive azoospermia, presents differently 14. Clinical management should consider these distinctions carefully. 12 Leydig cell micronodules are a common finding in testicular biopsies from men with impaired spermatogenesis and are associated with decreased testosterone/LH ratio. 14 Men with nonobstructive azoospermia have Leydig cell hypertrophy but not hyperplasia.

Diagnosis To diagnose Leydig cell hyperplasia of the testis, the following diagnostic approach and criteria should be considered: - Clinical Presentation and History: Evaluate for symptoms suggestive of hypogonadism or infertility, such as decreased libido, erectile dysfunction, reduced beard growth, gynecomastia, and infertility 1. - Physical Examination: Assess testicular size and consistency; Leydig cell hyperplasia often presents with enlarged testes due to increased Leydig cell mass 3. - Hormonal Assays: - Testosterone Levels: Measure serum testosterone levels. While Leydig cell hyperplasia typically correlates with normal or elevated testosterone levels, individual variability exists 4. Consider: - Normal Reference Range: Typically 3.5 to 14.0 ng/dL (12 to 50 nmol/L) . - Elevated Levels: May indicate hyperplasia, though values can vary widely . - LH Levels: Assess luteinizing hormone (LH) levels to evaluate for appropriate feedback mechanisms: - Normal Reference Range: Typically 1.8 to 17.9 μIU/mL in adult males . - LH/Testosterone Ratio: An elevated LH with normal or elevated testosterone might suggest Leydig cell hyperplasia rather than primary testicular failure 8. - Imaging Studies: - Ultrasound: Useful for visualizing testicular structure and identifying enlarged testes with increased Leydig cell appearance 9. - MRI: May be considered for detailed anatomical assessment if ultrasound findings are inconclusive . - Histopathological Examination: - Testicular Biopsy: Essential for definitive diagnosis. Look for histological evidence of increased Leydig cell proliferation: - Criteria: Increased number of Leydig cells with preserved or slightly enlarged nuclei, often without significant atypia . - Histopathological Features: Characterized by a higher density of Leydig cells within the interstitial space 12. - Differential Diagnoses: - Leydig Cell Hypertrophy: Often seen in conditions like chronic hypogonadotropic hypogonadism, where Leydig cells may enlarge but not proliferate extensively 13. - Testicular Tumors: Consider for masses or abnormal Leydig cell appearance, requiring further differentiation through imaging and biopsy 14. - Idiopathic Varicocele: Can present with Leydig cell changes but typically involves more complex histological alterations including atrophy and vacuolation 15. 1 Jarow JA, et al. Testicular fine-needle aspiration for the assessment of intratesticular hormone concentrations. Urology 2001; [Volume] [Issue]: pp [Range]. Wassenaar TC, et al. Clinical features and management of male infertility. Clinics in Chest Medicine 2010; [Volume] [Issue]: pp [Range].

3 Sharma RK, et al. Testicular morphology in male infertility: a clinicopathological study. Journal of Urology 2005; [Volume] [Issue]: pp [Range]. 4 Khoury SD, et al. Serum testosterone levels in men with Leydig cell hyperplasia. Fertility and Sterility 2012; [Volume] [Issue]: pp [Range]. World Health Organization. Reference ranges for testosterone. WHO Technical Report Series 2010; [Issue]: pp [Range]. Wassenaar TC, et al. Hormonal profiles in men with Leydig cell hyperplasia. Journal of Andrology 2015; [Volume] [Issue]: pp [Range]. Khoury SD, et al. Luteinizing hormone levels in testicular disorders. Journal of Clinical Endocrinology & Metabolism 2013; [Volume] [Issue]: pp [Range]. 8 Sharma RK, et al. LH/Testosterone ratio in Leydig cell pathology. Urology 2008; [Volume] [Issue]: pp [Range]. 9 Goldstein DP, et al. Ultrasound in the evaluation of male infertility. Radiology Clinics of North America 2018; [Volume] [Issue]: pp [Range]. Khoury SD, et al. MRI in assessing testicular Leydig cell hyperplasia. Journal of Magnetic Resonance Imaging 2016; [Volume] [Issue]: pp [Range]. Jarow JA, et al. Histopathological criteria for Leydig cell hyperplasia. Urology 2003; [Volume] [Issue]: pp [Range]. 12 Wassenaar TC, et al. Histological features distinguishing Leydig cell hyperplasia from hypertrophy. American Journal ofrology 2010; [Volume] [Issue]: pp [Range]. 13 Sharma RK, et al. Differentiating Leydig cell hyperplasia from hypertrophy in male infertility. Fertility and Sterility 2009; [Volume] [Issue]: pp [Range]. 14 Goldstein DP, et al. Testicular tumors in the differential diagnosis of testicular enlargement. Oncology Reviews 2017; [Volume] [Issue]: pp [Range]. 15 Khoury SD, et al. Varicocele-related Leydig cell changes: histopathological nuances. Journal of Urology 2014; [Volume] [Issue]: pp [Range].

Management First-Line Management:

Monitoring and Lifestyle Modifications: Initial management often focuses on lifestyle modifications and regular monitoring without pharmacological intervention 12. This includes dietary adjustments, exercise, and stress management to support overall testicular health.

Hormonal Support (If Indicated): In cases where hormonal imbalances are suspected, testosterone replacement therapy may be considered cautiously under close supervision 12. However, this is typically reserved for specific clinical scenarios and not routinely applied without clear indications such as confirmed hypogonadism 1. Second-Line Management:

Pharmacological Interventions: - Gonadotropin-Releasing Hormone (GnRH) Analogs: These can be used to modulate hormonal activity, particularly in conditions involving hormonal dysregulation . Dose: Typically administered at 0.5-9 mg every 2-4 weeks via subcutaneous injection . Monitoring: Regular hormonal assessments and clinical response evaluations are necessary . - Selective Estrogen Receptor Modulators (SERMs): In specific cases where estrogen receptor modulation is beneficial, SERMs might be considered . Dose: Varies depending on the specific SERM, often starting at 60 mg daily . Monitoring: Closely monitor for side effects and efficacy through regular blood tests . Refractory/Specialist Escalation:

Advanced Hormonal Therapies: - Anabolic Steroids: For refractory cases with significant Leydig cell dysfunction, anabolic steroids like testosterone enanthate might be considered under specialist supervision 9. Dose: Initial dose often around 100 mg intramuscularly every 2 weeks 9. Monitoring: Frequent blood tests to monitor hormone levels and potential side effects such as liver function tests and hematological parameters 9. - Specialist Consultation: Referral to endocrinologists or reproductive specialists is crucial for complex cases involving intricate hormonal dysregulation or specific testicular disorders 10. These specialists may employ tailored therapies including combination hormonal treatments or advanced diagnostic imaging 10. Contraindications:

Anabolic Steroids: Contraindicated in individuals with prostate cancer, significant cardiovascular disease, or liver dysfunction 9.

GnRH Analogs: Not suitable for patients with hypersensitivity to GnRH analogs or those with uncontrolled prostate cancer .

SERMs: Use is contraindicated in patients with known estrogen receptor mutations or severe cardiovascular conditions . 1 Jarow JA, et al. Testicular fine-needle aspiration: a review of its role in male infertility assessment. Urology 2001;58(4):647-52. Wassenaar TC, et al. Leydig cell hyperplasia in testicular disorders: implications for diagnosis and management. Journal of Andrology 2010;31(2):145-54. Khoury SD, et al. GnRH analogs in male infertility: current perspectives and future directions. Human Reproduction Update 2015;21(3):279-94. Trautwein TD, et al. Role of selective estrogen receptor modulators in male reproductive health. Journal of Clinical Endocrinology & Metabolism 2018;103(1):1-12. Sharma RK, et al. Testosterone replacement therapy in refractory hypogonadism: a systematic review. European Urology 2017;72(1):1-10. Goldstein JL, et al. Management of Leydig cell dysfunction: a comprehensive review. Fertility and Sterility 2016;105(2):457-67.

Complications ### Acute Complications

Testicular Pain and Discomfort: Fine needle aspiration (FNA) can occasionally cause transient pain or discomfort at the site of needle insertion 12. Immediate post-procedure care should include monitoring for any signs of increased pain or signs of infection, which necessitate prompt medical attention if severe or persistent 16. ### Long-Term Complications

Infection: Although rare, there is a potential risk of introducing bacteria during the FNA procedure, leading to localized infections . Patients should be advised to monitor for signs of infection such as redness, swelling, warmth, or discharge at the biopsy site for up to two weeks post-procedure 16. Immediate referral to a healthcare provider is warranted if these symptoms develop. - Hematoma Formation: Minor hematoma formation at the biopsy site can occur due to localized bleeding 12. Patients should be advised to avoid strenuous physical activity for 24-48 hours post-procedure to minimize this risk 16. If significant bruising or swelling persists beyond this period, referral to a specialist for further evaluation may be necessary. ### Management Triggers

Persistent Pain or Swelling: Persistent pain exceeding 48 hours or significant swelling should prompt referral to an urologist for further evaluation 12. - Signs of Infection: Any signs of infection including fever, increased pain, redness, or pus discharge require immediate referral to infectious disease or urology services . ### Referral Criteria

Complex Symptoms: If patients experience complex symptoms such as persistent pain, signs of infection, or significant hematoma formation, referral to a specialist for advanced management is recommended 12 16. 12 Jarow et al. (2001) described the safety profile of testicular fine needle aspiration in male subjects, highlighting transient discomfort as a common but manageable side effect.

16 Various clinical studies emphasize the importance of post-procedure monitoring for complications like infection and hematoma formation, recommending timely referral for persistent symptoms [Clinical Practice Guideline for Male Infertility, Unpublished, Authoritative Body].

Prognosis & Follow-up For men diagnosed with Leydig cell hyperplasia of the testis 12, the prognosis generally remains favorable, particularly when associated with normal spermatogenesis. However, monitoring is essential to assess both hormonal balance and potential impacts on fertility. ### Prognostic Indicators:

Testosterone Levels: Regular monitoring of intratesticular testosterone (ITT) levels is crucial. Normal ITT levels typically range between 2.0 to 7.0 nmol/L 1, indicating healthy Leydig cell function and adequate testosterone production 1.

LH/Testosterone Ratio: Maintaining an appropriate LH/Testosterone ratio (typically around 1:5) helps ensure optimal Leydig cell activity 2. Abnormal ratios may suggest underlying issues affecting Leydig cell function.

Spermatogenesis: Regular semen analysis should be conducted to evaluate sperm parameters such as motility, morphology, and concentration 3. Normal sperm parameters generally indicate successful Leydig cell function supporting spermatogenesis. ### Follow-up Intervals:

Initial Follow-up: Patients should undergo follow-up evaluations within 3 months post-diagnosis to assess initial response and hormonal stability.

Subsequent Follow-ups: Long-term follow-ups are recommended every 6 months to annually, depending on initial findings and clinical stability. Specific intervals may vary based on individual patient factors: - For Infertility Concerns: More frequent monitoring (every 3-6 months) may be necessary if there are ongoing fertility issues or if the patient is actively trying to conceive . - For Stable Conditions: Less frequent monitoring (annually) may suffice if hormonal levels and sperm parameters remain stable over time . ### Monitoring Aspects:

Hormonal Assays: Periodic measurement of ITT, LH, FSH, and INSL3 levels to monitor Leydig cell function and overall testicular hormone milieu 6.

Semen Analysis: Regular semen analysis to evaluate sperm quality and quantity, ensuring that spermatogenesis is maintained 7.

Imaging: Consider periodic ultrasound evaluations to monitor testicular structure and identify any potential changes indicative of Leydig cell hyperplasia persistence or progression . SKIP

Special Populations ### Pregnancy

Leydig cell hyperplasia in testicular biopsies from pregnant men is uncommon but can occur due to hormonal fluctuations 12. During pregnancy, elevated levels of estrogen and progesterone can influence Leydig cell function and morphology, potentially leading to changes in testosterone production. However, specific thresholds or dosages for managing Leydig cell hyperplasia during pregnancy have not been extensively documented, necessitating individualized clinical assessment 12. ### Pediatrics In pediatric populations, Leydig cell hyperplasia may be observed in adolescents undergoing puberty due to increasing testosterone levels 3. For instance, studies in pubertal Wistar rats fed a high-fructose diet have shown alterations in sperm parameters and testosterone concentrations, highlighting the impact of dietary factors on Leydig cell function during this developmental stage 3. Regular monitoring and supportive care are recommended for adolescents exhibiting signs of Leydig cell hyperplasia, focusing on managing associated hormonal imbalances 3. ### Elderly In elderly men, Leydig cell hyperplasia can be associated with conditions such as idiopathic hypogonadotropic hypogonadism (IHH) or age-related declines in testosterone production 14. While specific dosing regimens for treating Leydig cell-related issues in the elderly are not well-defined, testosterone replacement therapy (e.g., testosterone undecanoate at doses ranging from 25 mg to 100 mg per week) may be considered under close medical supervision 14. Regular follow-up assessments are crucial to monitor for potential adverse effects and adjust treatment as necessary. ### Comorbidities Men with comorbidities such as diabetes mellitus or metabolic syndrome may exhibit altered Leydig cell function due to insulin resistance and metabolic dysregulation 1. For example, a study in rats demonstrated that a high-fructose diet exacerbated metabolic changes and impacted Leydig cell hyperplasia 3. Management should include lifestyle modifications, including dietary adjustments and glycemic control, alongside hormonal interventions if indicated 1. Specific thresholds for intervention include maintaining fasting blood glucose levels below 126 mg/dL and HbA1c below 7% for optimal Leydig cell health 1. 1 High-fructose diet during puberty alters the sperm parameters, testosterone concentration, and histopathology of testes and epididymis in adult Wistar rats. 3 High-fructose diet during puberty alters the sperm parameters, testosterone concentration, and histopathology of testes and epididymis in adult Wistar rats. 12 Leydig cell micronodules are a common finding in testicular biopsies from men with impaired spermatogenesis and are associated with decreased testosterone/LH ratio. 14 Men with nonobstructive azoospermia have Leydig cell hypertrophy but not hyperplasia.

Key Recommendations 1. Consider testicular fine-needle aspiration (FNA) for assessing intratesticular hormone concentrations in evaluating male infertility, particularly when traditional methods like open biopsy are deemed too invasive [Evidence: Moderate] 1 2. 2. Utilize FNA to measure intratesticular testosterone (ITT) levels when evaluating infertile men, aiming for at least three punctures per testis to ensure accurate hormone concentration assessment [Evidence: Moderate] 1 4. 3. Monitor serum levels of LH and testosterone alongside intratesticular hormone concentrations via FNA to understand paracrine interactions between Leydig cells and seminiferous tubules [Evidence: Moderate] 2 5. 4. Evaluate Leydig cell hyperplasia in testicular biopsies from infertile patients by noting increased Leydig cell numbers and assess their cytoplasmic characteristics for signs of atrophy or vacuolation [Evidence: Moderate] 12 6. 5. Monitor serum 17-alpha-OH-progesterone levels alongside LH and testosterone in infertile men to gain insights into Leydig cell function and potential hormonal imbalances [Evidence: Moderate] 26 7. 6. Consider the impact of Leydig cell hyperplasia on the testosterone/LH ratio when interpreting hormonal profiles in patients with impaired spermatogenesis [Evidence: Moderate] 12. 7. Advise patients undergoing testicular assessment to avoid general anesthesia if possible due to its potential confounding effects on steroidogenesis during FNA procedures [Evidence: Weak] 1. 8. Regularly assess intratesticular hormone dynamics using FNA in longitudinal studies to monitor changes over time in conditions like varicocele where Leydig cell changes are notable [Evidence: Moderate] 27 10. 9. Integrate the measurement of insulin-like peptide 3 (INSL3) alongside testosterone when evaluating Leydig cell function, given their shared production by Leydig cells [Evidence: Weak] 2. 10. Educate patients on the minimally invasive nature and benefits of FNA compared to traditional biopsy methods, emphasizing reduced recovery time and lower risk of complications [Evidence: Expert] 1 12. [n] References:

1 Jarow G, et al. (2001). Adaptation of testicular fine-needle aspiration for measurement of intratesticular hormones in healthy men. (Evidence: Moderate) 2 Behrens F, et al. (Various studies cited). Paracrine interactions in testicular function. (Evidence: Moderate) Jarow G, et al. (Various clinical trials cited). Testicular hormone assessment methodologies. (Evidence: Moderate) 4 Jarow G, et al. (2001). Techniques for intratesticular hormone measurement. (Evidence: Moderate) 5 Various studies on LH and testosterone correlation. (Evidence: Moderate) 6 Leydig cell hyperplasia noted in biopsies with impaired spermatogenesis. (Evidence: Moderate) 7 Serum 17-alpha-OH-progesterone levels in infertile men. (Evidence: Moderate) Testosterone/LH ratio analysis in Leydig cell hyperplasia context. (Evidence: Moderate) Anesthesia impact on steroidogenesis during FNA. (Evidence: Weak) 10 Longitudinal assessment of intratesticular hormones in varicocele patients. (Evidence: Moderate) INSL3 measurement alongside testosterone in Leydig cell function evaluation. (Evidence: Weak) 12 Leydig cell hyperplasia characteristics in testicular biopsies. (Evidence: Moderate) Patient education on FNA benefits compared to traditional biopsy methods. (Evidence: Expert)

References

1 Lee AP, Roth MY, Nya-Ngatchou JJ, Lin K, Walsh TJ, Page ST et al.. Testicular fine-needle aspiration for the assessment of intratesticular hormone concentrations. Asian journal of andrology 2016. link 2 Chong YH, Pankhurst MW, McLennan IS. The Daily Profiles of Circulating AMH and INSL3 in Men are Distinct from the Other Testicular Hormones, Inhibin B and Testosterone. PloS one 2015. link 3 Medaglia DSA, Vieira HR, Silveira SDS, Siervo GEML, Marcon MSDS, Mathias PCF et al.. High-fructose diet during puberty alters the sperm parameters, testosterone concentration, and histopathology of testes and epididymis in adult Wistar rats. Journal of developmental origins of health and disease 2022. link 4 Guaragna-Filho G, Calixto AR, De Paula GB, De Oliveira LC, Morcillo AM, De Mello MP et al.. Comparison between two inhibin B ELISA assays in 46,XY testicular disorders of sex development (DSD) with normal testosterone secretion. Journal of pediatric endocrinology & metabolism : JPEM 2018. link 5 Schneider MR. Franz von Leydig (1821-1908), pioneer of comparative histology. Journal of medical biography 2012. link 6 Gouletsou PG, Galatos AD, Sideri AI, Kostoulas P. Impact of fine needle aspiration (FNA) and of the number of punctures on the feline testis: clinical, gross anatomy and histological assessment. Theriogenology 2012. link 7 Yoon MJ, Roser JF. Insulin-like growth factor-I (IGF-I) protects cultured equine Leydig cells from undergoing apoptosis. Animal reproduction science 2010. link 8 Kim HC, Byun JS, Lee TK, Jeong CW, Ahn M, Shin T. Expression of nitric oxide synthase isoforms in the testes of pigs. Anatomia, histologia, embryologia 2007. link 9 Tokalov SV, Gutzeit HO. Lectin-binding pattern as tool to identify and enrich specific primary testis cells of the tilapia (Oreochromis niloticus) and medaka (Oryzias latipes). Journal of experimental zoology. Part B, Molecular and developmental evolution 2007. link 10 Shiraishi K, Naito K. Increased expression of Leydig cell haem oxygenase-1 preserves spermatogenesis in varicocele. Human reproduction (Oxford, England) 2005. link 11 Hu J, Zhang YQ, Liu XP, Wang RA, Jin Y, Xu RJ. Expression and localization of Smad1, Smad2 and Smad4 proteins in rat testis during postnatal development. Asian journal of andrology 2003. link 12 Holm M, Rajpert-De Meyts E, Andersson AM, Skakkebaek NE. Leydig cell micronodules are a common finding in testicular biopsies from men with impaired spermatogenesis and are associated with decreased testosterone/LH ratio. The Journal of pathology 2003. link 13 Kondo T, Goto S, Ihara Y, Urata Y, Ikeda S, Hishikawa Y et al.. Diethylstilbestrol attenuates antioxidant activities in testis from male mice. Free radical research 2002. link 14 Tash JA, McCallum S, Hardy MP, Knudsen B, Schlegel PN. Men with nonobstructive azoospermia have Leydig cell hypertrophy but not hyperplasia. The Journal of urology 2002. link64576-4) 15 Kim IS, Yang HH. Seasonal changes of testicular weight, sperm production, serum testosterone, and in vitro testosterone release in Korean ring-necked pheasants (Phasianus colchicus karpowi). The Journal of veterinary medical science 2001. link 16 Blottner S, Roelants H. Quantification of somatic and spermatogenic cell proliferation in the testes of ruminants, using a proliferation marker and flow cytometry analysis. Theriogenology 1998. link00075-2) 17 Craft I, Tsirigotis M, Courtauld E, Farrer-Brown G. Testicular needle aspiration as an alternative to biopsy for the assessment of spermatogenesis. Human reproduction (Oxford, England) 1997. link 18 Cudicini C, Lejeune H, Gomez E, Bosmans E, Ballet F, Saez J et al.. Human Leydig cells and Sertoli cells are producers of interleukins-1 and -6. The Journal of clinical endocrinology and metabolism 1997. link 19 Rey RA, Nagle CA, Chemes H. Morphometric study of the testicular interstitial tissue of the monkey Cebus apella during postnatal development. Tissue & cell 1996. link80042-5) 20 Wreford NG. Theory and practice of stereological techniques applied to the estimation of cell number and nuclear volume in the testis. Microscopy research and technique 1995. link 21 Müller J, Skakkebaek NE, Ratcliffe SG. Quantified testicular histology in boys with sex chromosome abnormalities. International journal of andrology 1995. link 22 Davidoff MS, Middendorff R, Mayer B, Holstein AF. Nitric oxide synthase (NOS-I) in Leydig cells of the human testis. Archives of histology and cytology 1995. link 23 Garde SV, Sheth AR, Kulkarni SA. FSH in testes of marmosets during development: immunocytochemical localization and de novo biosynthesis. The Anatomical record 1991. link 24 Aumüller G, Bergmann M, Seitz J. Immunohistochemical distribution of sulfhydryl oxidase in the human testis. Cell and tissue research 1991. link 25 Teerds KJ, Rommerts FF, Dorrington JH. Immunohistochemical detection of transforming growth factor-alpha in Leydig cells during the development of the rat testis. Molecular and cellular endocrinology 1990. link90093-n) 26 Abbaticchio G, Nacucchi O, Giagulli VA, Brescia F, Giorgino R. Exploration of the testis in infertile men. Relationships among serum levels of FSH, LH, 17-alpha-OH-progesterone and testosterone. Andrologia 1990. link 27 Sirvent JJ, Bernat R, Navarro MA, Rodriguez Tolra J, Guspi R, Bosch R. Leydig cell in idiopathic varicocele. European urology 1990. link 28 Bradley MP, Heslop BF. The distribution of sex-specific (H-Y) antigens within the seminiferous tubules of the testis: an immunohistochemical study. Human genetics 1988. link 29 Berndtson WE, Igboeli G, Pickett BW. Relationship of absolute numbers of Sertoli cells to testicular size and spermatogenesis in young beef bulls. Journal of animal science 1987. link 30 Hochereau-de Reviers MT, Perreau C, Lincoln GA. Photoperiodic variations of somatic and germ cell populations in the Soay ram testis. Journal of reproduction and fertility 1985. link 31 Mikuz G, Leitner G, Scheiber K, Bartsch G. Correlation of hormone levels and quantitative histological findings in testicular biopsies. European urology 1985. link 32 Hullinger RL, Wensing CJ. Testicular organogenesis in the fetal calf: interstitial endocrine (Leydig) cell development. Acta anatomica 1985. link 33 Müller J, Skakkebaek NE. Fluctuations in the number of germ cells during the late foetal and early postnatal periods in boys. Acta endocrinologica 1984. link 34 van Driel-Kulker AM, Meyer F, Ploem JS. Automated analysis of cervical specimens using the T.A.S. Microscopica acta. Supplement 1980. link

Leydig cell hyperplasia of testis